Clinical trials: Adalimumab
Juvenile Idiopathic Arthritis Associated Uveitis
Biologic Therapy in Pediatric JIA Uveitis
Juvenile Idiopathic Arthritis (JIA) remains the most common systemic disorder associated with pediatric uveitis. Studies estimate that 28-67% of patients with JIA-associated uveitis develop ocular complications, with 12%…
- Trial name
- NCT05540743
- Testing
- biologic DMARDs
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Kasr El Aini Hospital
Psoriasis
Adalimumab Biosimilar in Clinical Practice
This is an observational, retrospective, multicenter, and descriptive study of patients treated with adalimumab biosimilar for psoriasis, according to clinical practice.
- Trial name
- NCT04808739
- Testing
- Adalimumab
- Where
- Spain
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Intestinal Behçet's Disease
A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease
To investigate efficacy, safety and pharmacokinetics of adalimumab subcutaneous (sc) for Japanese subjects with intestinal Behçet's disease who are refractory to conventional therapies.
- Trial name
- NCT01243671
- Testing
- Adalimumab
- Where
- 12 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
Special Investigation (Long-term Investigation) in Patients With Crohn's Disease
This study of Humira will be conducted to obtain information on the safety (especially profile of malignant tumors and serious infections) and effectiveness in patients with Crohn's disease who are receiving Humira for a long…
- Trial name
- NCT01464333
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ulcerative Colitis
Special Investigation in Patients With Ulcerative Colitis
This investigation will be conducted to obtain the following information regarding the use of Humira 40 mg Syringe 0.8 mL for Subcutaneous Injection in patients with Ulcerative Colitis. 1.
- Trial name
- NCT01947816
- Volunteers
- 1,621 people
- Sponsor
- AbbVie
Generalized Pustular Psoriasis (GPP), Adalimumab
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently…
- Conditions
- Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese
- Trial name
- NCT02533375
- Testing
- Adalimumab
- Volunteers
- 10 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis
The purpose of this study was to collect data on the incidence of adverse drug reactions, infections and malignant tumors, as well as factors that might affect the safety and effectiveness of Humira® (adalimumab; 40mg/0.8 mL) in…
- Trial name
- NCT01163318
- Volunteers
- 552 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.
- Trial name
- ped PsO rPMS (NCT03925441)
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment
A potential application of therapeutic drug monitoring is to predict efficacy after switch to another biological in the case of inefficacy of the previous TNF-inhibitor (TNFi) in rheumatoid arthritis (RA) patients.
- Trial name
- ADDORA-switch (NCT04251741)
- Testing
- Adalimumab trough concentration, Usual care
- Where
- 2 sites in Netherlands
- Volunteers
- 86 people
- Sponsor
- Reade Rheumatology Research Institute
Uveitis, Diabetic Retinopathy
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study
Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders.
- Conditions
- Uveitis, Diabetic Retinopathy, Choroidal Neovascularization
- Trial name
- ADA01 (NCT00855608)
- Testing
- adalimumab
- Where
- Lebanon
- Volunteers
- 15 people
- Sponsor
- Rafic Hariri University Hospital
Crohn's Disease, Rheumatoid Arthritis
OTIS Humira Pregnancy Registry
The purpose of the OTIS Autoimmune disease in pregnancy study is to monitor planned and unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic effect of these medications and to follow live…
- Trial name
- NCT01086059
- Where
- United States
- Volunteers
- 944 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Crohn's Disease
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
- Trial name
- CAPE (NCT02130362)
- Where
- 148 sites in United States, Bosnia and Herzegovina and 20 more
- Volunteers
- 1,446 people
- Sponsor
- AbbVie
Ulcerative Colitis
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT02065557
- Testing
- Adalimumab
- Where
- 60 sites in United States, Australia and 12 more
- Volunteers
- 101 people
- Sponsor
- AbbVie
Crohn's Disease
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.
- Trial name
- NCT00445432
- Testing
- adalimumab
- Where
- 29 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Abbott
JIA Associated Uveitis
Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
To asses the use of golimumab, a fully humanized anti-TNF Alpha monoclonal antibody, in juvenile idiopathic Arthritis-associated uveitis refractory to adalimumab.
- Trial name
- NCT04200833
- Testing
- Golimumab
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to evaluate the incidence of serious adverse events (SAEs) within 12, 26, and 52 weeks after treatment; as well as the…
- Trial name
- NCT07564505
- Testing
- Adalimumab Solution for Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Focal Segmental Glomerulosclerosis
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental…
- Trial name
- FONTII (NCT00814255)
- Testing
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Where
- 18 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
The purpose of the study is to collect preliminary data on whether the drug adalimumab (also called Humira) can decrease pain and stiffness, improve quality of life, and is safe in people with mucopolysaccharidosis type I, II, or…
- Conditions
- Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
- Trial name
- NCT02437253
- Testing
- Adalimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Rasmussen Encephalitis
Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term
Since the initial study of cases reported between 2009 and 2015, adalimumab has become in France the immunomodulatory reference treatment used after failure of corticosteroids and immunoglobulins before a possible recourse to the…
- Trial name
- NCT04003922
- Testing
- Adalimumab treatment
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille